These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18663489)

  • 1. Meta-basic estimates the size of druggable human genome.
    Plewczynski D; Rychlewski L
    J Mol Model; 2009 Jun; 15(6):695-9. PubMed ID: 18663489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical genomics: bridging the gap between the proteome and therapeutics.
    Falb D; Jindal S
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):532-9. PubMed ID: 12197311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrogating the druggable genome with structural informatics.
    Hambly K; Danzer J; Muskal S; Debe DA
    Mol Divers; 2006 Aug; 10(3):273-81. PubMed ID: 17031532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a subtractive genomics approach for in silico identification and characterization of novel drug targets in Mycobacterium tuberculosis F11.
    Hosen MI; Tanmoy AM; Mahbuba DA; Salma U; Nazim M; Islam MT; Akhteruzzaman S
    Interdiscip Sci; 2014 Mar; 6(1):48-56. PubMed ID: 24464704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DrugBank: a comprehensive resource for in silico drug discovery and exploration.
    Wishart DS; Knox C; Guo AC; Shrivastava S; Hassanali M; Stothard P; Chang Z; Woolsey J
    Nucleic Acids Res; 2006 Jan; 34(Database issue):D668-72. PubMed ID: 16381955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome.
    Li L; Bum-Erdene K; Baenziger PH; Rosen JJ; Hemmert JR; Nellis JA; Pierce ME; Meroueh SO
    Nucleic Acids Res; 2010 Jan; 38(Database issue):D765-73. PubMed ID: 19923229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of chemical design tools to transform proteomics data into drug candidates.
    Dean PM; Zanders ED
    Biotechniques; 2002 Mar; Suppl():28-33. PubMed ID: 11906004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review and comparative assessment of similarity-based methods for prediction of drug-protein interactions in the druggable human proteome.
    Wang C; Kurgan L
    Brief Bioinform; 2019 Nov; 20(6):2066-2087. PubMed ID: 30102367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural systems pharmacology: a new frontier in discovering novel drug targets.
    Tan H; Ge X; Xie L
    Curr Drug Targets; 2013 Aug; 14(9):952-8. PubMed ID: 23597016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural proteomics: toward high-throughput structural biology as a tool in functional genomics.
    Yee A; Pardee K; Christendat D; Savchenko A; Edwards AM; Arrowsmith CH
    Acc Chem Res; 2003 Mar; 36(3):183-9. PubMed ID: 12641475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DGIdb: mining the druggable genome.
    Griffith M; Griffith OL; Coffman AC; Weible JV; McMichael JF; Spies NC; Koval J; Das I; Callaway MB; Eldred JM; Miller CA; Subramanian J; Govindan R; Kumar RD; Bose R; Ding L; Walker JR; Larson DE; Dooling DJ; Smith SM; Ley TJ; Mardis ER; Wilson RK
    Nat Methods; 2013 Dec; 10(12):1209-10. PubMed ID: 24122041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates.
    Jónsdóttir SO; Jørgensen FS; Brunak S
    Bioinformatics; 2005 May; 21(10):2145-60. PubMed ID: 15713739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T3DB: a comprehensively annotated database of common toxins and their targets.
    Lim E; Pon A; Djoumbou Y; Knox C; Shrivastava S; Guo AC; Neveu V; Wishart DS
    Nucleic Acids Res; 2010 Jan; 38(Database issue):D781-6. PubMed ID: 19897546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging trends in high-throughput screening.
    Entzeroth M
    Curr Opin Pharmacol; 2003 Oct; 3(5):522-9. PubMed ID: 14559099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review: prediction of in vivo fates of proteins in the era of genomics and proteomics.
    Nakai K
    J Struct Biol; 2001; 134(2-3):103-16. PubMed ID: 11551173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DrugBank: a knowledgebase for drugs, drug actions and drug targets.
    Wishart DS; Knox C; Guo AC; Cheng D; Shrivastava S; Tzur D; Gautam B; Hassanali M
    Nucleic Acids Res; 2008 Jan; 36(Database issue):D901-6. PubMed ID: 18048412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics in the post-genome era.
    Yu U; Lee SH; Kim YJ; Kim S
    J Biochem Mol Biol; 2004 Jan; 37(1):75-82. PubMed ID: 14761305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics in biomarker discovery and drug development.
    He QY; Chiu JF
    J Cell Biochem; 2003 Aug; 89(5):868-86. PubMed ID: 12874822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated structural proteomics approach along the druggable genome of Corynebacterium pseudotuberculosis species for putative druggable targets.
    Radusky LG; Hassan S; Lanzarotti E; Tiwari S; Jamal S; Ali J; Ali A; Ferreira R; Barh D; Silva A; Turjanski AG; Azevedo VA
    BMC Genomics; 2015; 16 Suppl 5(Suppl 5):S9. PubMed ID: 26041381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.